Side-by-side · Research reference
LiraglutidevsN-Acetyl Epitalon Amidate
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship14/45 cited
BAnimal-StrongHUMAN-REVIEWED12/45 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
01Mechanism of Action
Parameter
Liraglutide
N-Acetyl Epitalon Amidate
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
—
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
N-Acetyl Epitalon Amidate
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Not specified in candidate papers
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
In vitro human cell cultureKhavinson 2004Khavinson 2003
Duration
Indefinite for chronic indication
Chronic treatment in aging culture
Sustained effect through late passages.
Reconstitution
Pre-filled commercial pen (no reconstitution)
—
Timing
Any time of day; consistent
—
Standard dose
—
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
Cell culture protocol
—
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
Modification stability
—
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
04Side Effects & Safety
Parameter
Liraglutide
N-Acetyl Epitalon Amidate
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
—
Pancreatitis risk
Rare; discontinue if suspected
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
—
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Heart rate
Modest ↑ resting HR (~2-3 bpm)
—
Pregnancy / OB
Contraindicated
—
Human safety data
—
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
Theoretical telomerase risk
—
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
05Administration Protocol
Parameter
Liraglutide
N-Acetyl Epitalon Amidate
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
3. Timing
Once daily, same time each day. Take with or without food.
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
5. Needle
Pen-supplied 32G needle.
—
06Stack Synergy
Liraglutide
— no documented stacks
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration